Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Historical Holders from Q2 2020 to Q3 2025

Symbol
KROS on Nasdaq
CUSIP
492327101
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
30.3M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
35.3M
Holdings value
$558M
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
149
Number of buys
81
Number of sells
-54
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Madison Avenue Partners, LP 6.4% $37.2M 2.61M Madison Avenue Partners, LP May 7, 2025
VANGUARD GROUP INC 6.32% $36.5M 2.57M The Vanguard Group Mar 31, 2025
TANG CAPITAL MANAGEMENT LLC 7.9% $38.3M 2.42M TANG CAPITAL MANAGEMENT, LLC Oct 15, 2025
ExodusPoint Capital Management, LP 6.3% $28.7M 1.91M ExodusPoint Capital Management, LP Nov 10, 2025
D. E. SHAW & CO, L.P. 5.1% $24.5M 1.55M D. E. Shaw & Co., L.P. Oct 20, 2025
ALKEON CAPITAL MANAGEMENT LLC 2.7% $15.6M 1.1M Alkeon Capital Management LLC Dec 31, 2024
FMR LLC 1.7% $10M 704K FMR LLC Jan 31, 2025
JPMORGAN CHASE & CO 0.2% -102% $1.62M -$35.1M 114K -95.6% JPMORGAN CHASE & CO. Apr 30, 2025

Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 35.3M $558M -$7.64M $15.82 149
2025 Q2 35.9M $480M +$53.9M $13.35 134
2025 Q1 32.8M $334M -$102M $10.19 154
2024 Q4 36.7M $582M -$99.6M $15.83 159
2024 Q3 34.9M $2.03B +$197M $58.07 163
2024 Q2 31.5M $1.44B -$2.07M $45.70 149
2024 Q1 31.3M $2.08B +$375M $66.20 143
2023 Q4 25.7M $1.02B +$111M $39.76 117
2023 Q3 22.8M $727M +$7.88M $31.88 103
2023 Q2 22.4M $900M +$13.2M $40.18 119
2023 Q1 22M $937M +$94.6M $42.70 127
2022 Q4 19.7M $948M +$89.7M $48.02 119
2022 Q3 18.1M $680M +$30M $37.62 105
2022 Q2 17.4M $480M +$10.3M $27.63 100
2022 Q1 16.4M $893M +$13.7M $54.38 100
2021 Q4 16.1M $944M +$68.4M $58.51 95
2021 Q3 13.7M $543M -$15.8M $39.56 85
2021 Q2 14.1M $599M -$43.6M $42.47 78
2021 Q1 14.4M $887M -$123M $61.55 82
2020 Q4 16M $1.13B +$301M $70.54 80
2020 Q3 11.8M $455M +$33.8M $38.57 49
2020 Q2 10.9M $410M +$410M $37.51 51